There were few surprises in today’s H1 2020 results, and Verona has performed financially in line with our expectations. The main news is it has FDA permission to investigate ensifentrine in a study for hospitalised Covid-19 patients that is set to begin in Q3 2020. The study will provide clinical information on ensifentrine in a new disease beyond COPD and cystic fibrosis, and that could be leveraged within the regulatory package for COPD or licensing agreements. We note the recognition of a co ....
14 Aug 2020
In line H1 2020 results – ensifentrine to be trialled in Covid-19 patients
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line H1 2020 results – ensifentrine to be trialled in Covid-19 patients
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
14 Aug 2020 -
Author:
Edward Thomason -
Pages:
4
There were few surprises in today’s H1 2020 results, and Verona has performed financially in line with our expectations. The main news is it has FDA permission to investigate ensifentrine in a study for hospitalised Covid-19 patients that is set to begin in Q3 2020. The study will provide clinical information on ensifentrine in a new disease beyond COPD and cystic fibrosis, and that could be leveraged within the regulatory package for COPD or licensing agreements. We note the recognition of a co ....